Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 14.5
(0.0%)
SEK 14.5
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.6 Million SEK | -7.08% |
| 2022 | 22.17 Million SEK | 239.78% |
| 2021 | 6.52 Million SEK | 2.75% |
| 2020 | 6.35 Million SEK | -16.57% |
| 2019 | 7.61 Million SEK | -6.31% |
| 2018 | 8.12 Million SEK | 26.15% |
| 2017 | 6.43 Million SEK | 60.72% |
| 2016 | 4 Million SEK | 534.12% |
| 2015 | 631.84 Thousand SEK | -26.28% |
| 2014 | 857.11 Thousand SEK | 1.78% |
| 2013 | 842.1 Thousand SEK | 91.93% |
| 2012 | 438.75 Thousand SEK | 613.58% |
| 2011 | 61.48 Thousand SEK | -15.36% |
| 2010 | 72.64 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 19.26 Million SEK | -6.49% |
| 2024 Q2 | 22.58 Million SEK | 17.25% |
| 2023 Q3 | 14.87 Million SEK | -34.21% |
| 2023 FY | 20.6 Million SEK | -7.08% |
| 2023 Q4 | 20.6 Million SEK | 38.52% |
| 2023 Q1 | 21.97 Million SEK | -0.87% |
| 2023 Q2 | 22.6 Million SEK | 2.85% |
| 2022 Q1 | 5.89 Million SEK | -9.73% |
| 2022 Q2 | 7.51 Million SEK | 27.54% |
| 2022 Q4 | 22.17 Million SEK | 201.91% |
| 2022 Q3 | 7.34 Million SEK | -2.24% |
| 2022 FY | 22.17 Million SEK | 239.78% |
| 2021 Q2 | 13.72 Million SEK | 115.68% |
| 2021 Q1 | 6.36 Million SEK | 0.2% |
| 2021 Q3 | 18.16 Million SEK | 32.34% |
| 2021 Q4 | 6.52 Million SEK | -64.07% |
| 2021 FY | 6.52 Million SEK | 2.75% |
| 2020 Q3 | 6.42 Million SEK | -28.54% |
| 2020 FY | 6.35 Million SEK | -16.57% |
| 2020 Q1 | 7.67 Million SEK | 0.78% |
| 2020 Q4 | 6.35 Million SEK | -1.17% |
| 2020 Q2 | 8.99 Million SEK | 17.22% |
| 2019 FY | 7.61 Million SEK | -6.31% |
| 2019 Q1 | 7.65 Million SEK | -5.77% |
| 2019 Q2 | 6.79 Million SEK | -11.3% |
| 2019 Q3 | 7.15 Million SEK | 5.42% |
| 2019 Q4 | 7.61 Million SEK | 6.33% |
| 2018 Q1 | 5.41 Million SEK | -15.88% |
| 2018 FY | 8.12 Million SEK | 26.15% |
| 2018 Q4 | 8.12 Million SEK | 37.59% |
| 2018 Q3 | 5.9 Million SEK | 10.41% |
| 2018 Q2 | 5.34 Million SEK | -1.28% |
| 2017 FY | 6.43 Million SEK | 60.72% |
| 2017 Q3 | 5.29 Million SEK | 60.13% |
| 2017 Q4 | 6.43 Million SEK | 21.72% |
| 2017 Q2 | 3.3 Million SEK | -20.1% |
| 2017 Q1 | 4.13 Million SEK | 8.09% |
| 2016 Q2 | 3.78 Million SEK | 0.0% |
| 2016 Q4 | 3.82 Million SEK | -12.39% |
| 2016 FY | 4 Million SEK | 534.12% |
| 2016 Q3 | 4.36 Million SEK | 15.4% |
| 2015 Q2 | 462.83 Thousand SEK | 26.14% |
| 2015 FY | 631.84 Thousand SEK | -26.28% |
| 2015 Q4 | 631.84 Thousand SEK | -36.38% |
| 2015 Q3 | 993.23 Thousand SEK | 114.6% |
| 2015 Q1 | 366.9 Thousand SEK | -57.19% |
| 2014 Q4 | 857.11 Thousand SEK | 0.0% |
| 2014 FY | 857.11 Thousand SEK | 1.78% |
| 2013 FY | 842.1 Thousand SEK | 91.93% |
| 2012 FY | 438.75 Thousand SEK | 613.58% |
| 2011 FY | 61.48 Thousand SEK | -15.36% |
| 2010 FY | 72.64 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -87.31% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.23% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.23% |
| Arcoma AB | 33.3 Million SEK | 38.147% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 93.752% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.369% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 92.64% |
| CellaVision AB (publ) | 212.32 Million SEK | 90.298% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -45.103% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -199.905% |
| C-Rad AB (publ) | 122.4 Million SEK | 83.17% |
| Duearity AB (publ) | 17.53 Million SEK | -17.515% |
| Dignitana AB (publ) | 37.56 Million SEK | 45.164% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -4.042% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.917% |
| Iconovo AB (publ) | 14.55 Million SEK | -41.545% |
| Integrum AB (publ) | 22.07 Million SEK | 6.671% |
| Luxbright AB (publ) | 7 Million SEK | -194.285% |
| Mentice AB (publ) | 163.55 Million SEK | 87.405% |
| OssDsign AB (publ) | 105.25 Million SEK | 80.429% |
| Paxman AB (publ) | 44.5 Million SEK | 53.717% |
| Promimic AB (publ) | 16.15 Million SEK | -27.509% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 66.864% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 3.185% |
| ScandiDos AB (publ) | 37.18 Million SEK | 44.602% |
| Sectra AB (publ) | 1.64 Billion SEK | 98.745% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 53.247% |
| Senzime AB (publ) | 58.06 Million SEK | 64.522% |
| SpectraCure AB (publ) | 14.97 Million SEK | -37.565% |
| Stille AB | 172.64 Million SEK | 88.067% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.438% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 91.778% |